Sanctuary Advisors LLC Boosts Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Sanctuary Advisors LLC grew its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 41.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,853 shares of the company’s stock after acquiring an additional 10,796 shares during the quarter. Sanctuary Advisors LLC’s holdings in Hims & Hers Health were worth $891,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. raised its holdings in shares of Hims & Hers Health by 370.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock worth $33,024,000 after buying an additional 1,075,355 shares during the period. Principal Securities Inc. grew its position in Hims & Hers Health by 48.2% in the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after acquiring an additional 1,002 shares during the last quarter. Rhumbline Advisers increased its stake in Hims & Hers Health by 93.8% in the fourth quarter. Rhumbline Advisers now owns 516,224 shares of the company’s stock worth $12,482,000 after purchasing an additional 249,854 shares during the period. New York State Teachers Retirement System lifted its position in shares of Hims & Hers Health by 3,284.6% during the fourth quarter. New York State Teachers Retirement System now owns 99,812 shares of the company’s stock worth $2,413,000 after purchasing an additional 96,863 shares during the last quarter. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Hims & Hers Health during the fourth quarter valued at $2,234,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $41.30 on Friday. The company’s 50-day simple moving average is $36.19 and its 200-day simple moving average is $26.46. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The stock has a market capitalization of $9.02 billion, a P/E ratio of 93.85 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling

In other news, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction on Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at approximately $4,659,976.07. The trade was a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 33,513 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94. Following the completion of the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $1,118,296.76. The trade was a 50.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,578 shares of company stock worth $38,080,320 in the last ninety days. 17.71% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Truist Financial increased their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research note on Wednesday. Finally, Bank of America lifted their target price on Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a research report on Thursday, February 20th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $35.71.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.